

Ukrainian pharmaceutical industry is trying to maintain drug supply

+56.7% y-o-y
average daily growth of pharmacy drug sales in packs from 24.02.2022 to 08.03.2022 in Ukraine



69%
the share of Ukrainian pharmaceutical manufacturers in pharmacy sales in Ukraine in packs (2020)

Status of Ukrainian pharmaceutical plants (as of 15.03.2022)



Companies, which status is unknown:
Fitofarm (Bahmut, Donetsk obl.), Viola (Zaporizhzhia), Lubnyfarm (Lybny, Poltavsk obl.), Monfarm (Monastyrishche, Cherkaska obl.), Sperko (Vinnytsya), Infuzia (Vinnytsya), Liktravy (Zhytomyr), Vishpha (Stanyshivka, Zhytomyrska obl.), Orisil-Pharm (Lviv), Novofarm-Biosynthesis (Novograd-Volynskiy, Zhytomyrska obl.).

Data source: company's web-sites, data received from pharmaceutical market participants

Since the war beginning drug demand has increased significantly. According to survey of Proxima Research, from 24.02.2022 to 08.03.2022 daily drug sales in packs rose by 56.7% y-o-y in average, while daily drug sales in monetary terms increased by 65.4% y-o-y in average.

According to our estimations, at least 50% of Ukrainian pharmaceutical plants continue working. But they face with difficulties connected to hostilities (for example, disruptions in supply chains, destruction of warehouses, lack of freight transport, threat to the lives of employees).

Many pharmacies in Ukraine are closed, so it is very difficult to deliver medicines to the end consumer. There is a shortage of some foreign-made medicines as the warehouses of international pharmaceutical companies remain closed.

Now Ukrainian pharmaceutical plants are trying to supply produced drugs at domestic market. But it is uncertain how long Ukrainian pharmaceutical plants will be able to work. Although in 2020 Ukrainian pharmaceutical manufacturers supplied 69% of drugs (in terms of packs) domestically, in the future it will be necessary to increase foreign supplies of medicines to Ukraine.

STOP THE WAR